PharmaOpinion
Demis Hassabis Raises $5 Billion in His Quest to Solve All Disease
Isomorphic is developing its own drug pipeline while designing medicines with Lilly, Novartis and Johnson & Johnson, putting it alongside the pharma giants as both a research partner and a drug developer.

The brief
- Isomorphic Labs raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, following a $2.1 billion Series B in May, totaling $7.1 billion in funding.
- The company utilizes an AI-driven drug design engine to generate and refine molecular designs, achieving unprecedented precision and speed in drug development.
- Isomorphic Labs has reported positive preclinical results in oncology and immunology and is moving toward clinical trials with its drug candidates.
Deployment
- Company
- Isomorphic Labs
- System
- Drug Design Engine
- Stage
- Announced
- financing amount
- 5 billion
Isomorphic Labs gave an AI agent a molecular design brief, including a biological target and the properties a potential drug would need. Over two to four days, the agent searched for designs that met those requirements. Scientists then made selected compounds and tested them, reporting that one successfully changed the target’s activity in the laboratory.
The brief
- Isomorphic Labs raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, following a $2.1 billion Series B in May, totaling $7.1 billion in funding.
- The company utilizes an AI-driven drug design engine to generate and refine molecular designs, achieving unprecedented precision and speed in drug development.
- Isomorphic Labs has reported positive preclinical results in oncology and immunology and is moving toward clinical trials with its drug candidates.
Deployment
- Company
- Isomorphic Labs
- System
- Drug Design Engine
- Stage
- Announced
- financing amount
- 5 billion
The company described that workflow in September. Now, a $5 billion financing will help expand the technology and move its drug candidates toward testing in people.
Announced on Tuesday (November 17, 2026), the Series C was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz (a16z) among the new investors and continued backing from Alphabet. It follows a $2.1 billion Series B in May, bringing the two rounds to $7.1 billion.
“Our drug design engine is generating molecules with unprecedented precision and speed,” said Demis Hassabis, Founder and CEO of Isomorphic Labs.
Founded in 2021, Isomorphic is building its own drug pipeline while designing medicines with Lilly, Novartis and Johnson & Johnson, operating as both a research partner and a drug developer. The London-headquartered company also has offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
The Alphabet-backed company reports positive preclinical results in oncology and immunology, with new funding supporting its move toward clinical trials. Part of the money will build the translational and clinical development capabilities needed to take laboratory findings into studies in people.
Choosing What to Make in the Lab
The Isomorphic Labs Drug Design Engine (IsoDDE) brings predictive models together with agents that generate and refine molecules. Its predictions help scientists assess how a molecule fits a protein and how strongly it binds, alongside properties that affect whether it could become a useful medicine.
In the September demonstration, the agent generated batches of designs and adjusted its search against the scientists’ specifications, including solubility and the ability to enter cells. The computational search ran over two to four days, followed by synthesis and laboratory testing of selected compounds.
Isomorphic has also reported progress on unfamiliar biological structures. In February, its models achieved more than twice AlphaFold 3’s accuracy on the hardest category of a protein–ligand structure benchmark.
Another example involved cereblon, a protein involved in marking other proteins for disposal. Using its amino acid sequence, IsoDDE reproduced an experimentally discovered hidden binding pocket, identifying another site researchers could investigate when designing molecules.
“Every week we are making repeatable scientific advancements enabled by our models,” said Max Jaderberg, President of Isomorphic Labs.
Building the Path Into Clinical Trials
Pharmaceutical partnerships are already extending the engine’s use. Isomorphic’s Novartis collaboration began in 2024 with three challenging targets and expanded in 2025 to include up to three additional programs.
Its Lilly collaboration focuses on small-molecule discovery against undisclosed targets, while its Johnson & Johnson work spans multiple types of therapeutics. Across these programs, Isomorphic describes teams reviewing evidence together and deciding which compounds to make and test next.
As AI produces more promising candidates, the capacity to test them becomes more consequential. Formation Bio Co-Founder and CEO Benjamine Liu said that faster discovery could leave the industry with more candidates than it can develop, creating a clinical-testing bottleneck.
Isomorphic’s financing supports work on both its models and the development infrastructure for its growing pipeline. Its next step is to advance the first therapeutic programs toward clinical trials.
“As a potential therapy gets closer to patients, the bar for data integrity becomes increasingly stringent,” said Mary Ellen Healy, who works in Clinical Operations at Isomorphic Labs.
Join the discussion
0 answers
People who run these systems answer here. Your verified role is shown, never your employer unless you choose.
Sign in with LinkedIn to answer
Read next
Chaos Predictions — every Monday
Where enterprise AI is heading next, read from the week’s deployments across banking, pharma, manufacturing and retail.
Free. One email every Monday. Unsubscribe in one click.












